Molecular and functional PET-fMRI measures of placebo analgesia in episodic migraine: Preliminary findings

Pain interventions with no active ingredient, placebo, are sometimes effective in treating chronic pain conditions. Prior studies on the neurobiological underpinnings of placebo analgesia indicate endogenous opioid release and changes in brain responses and functional connectivity during pain antici...

Full description

Saved in:
Bibliographic Details
Published in:NeuroImage clinical 2018-01, Vol.17, p.680-690
Main Authors: Linnman, Clas, Catana, Ciprian, Petkov, Mike P., Chonde, Daniel Burje, Becerra, Lino, Hooker, Jacob, Borsook, David
Format: Article
Language:English
Subjects:
Adult
Analgesia
Brain - diagnostic imaging
Brain - metabolism
Brain - physiopathology
Female
Humans
Injections, Intravenous
Magnetic Resonance Imaging
Male
Migraine Disorders - diagnostic imaging
Migraine Disorders - metabolism
Migraine Disorders - physiopathology
Multimodal Imaging
Pain Measurement
Pain Threshold
Placebo Effect
Placebos - administration & dosage
Positron-Emission Tomography
Receptors, Opioid - metabolism
Regular
Sodium Chloride - administration & dosage
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Pain interventions with no active ingredient, placebo, are sometimes effective in treating chronic pain conditions. Prior studies on the neurobiological underpinnings of placebo analgesia indicate endogenous opioid release and changes in brain responses and functional connectivity during pain anticipation and pain experience in healthy subjects. Here, we investigated placebo analgesia in healthy subjects and in interictal migraine patients (n=9) and matched healthy controls (n=9) using 11C-diprenoprhine Positron Emission Tomography (PET) and simultaneous functional Magnetic Resonance Imaging (fMRI). Intravenous saline injections (the placebo) led to lower pain ratings, but we did not find evidence for an altered placebo response in interictal migraine subjects as compared to healthy subjects. •Simultaneous fMRI and 11C-Diprenoprhine PET of migraineurs and controls before and after placebo analgesia•Placebo led to an overall reduction in pain ratings, with no significant differences between patients and controls•Structural changes in migraine, but no effects of placebo or diagnosis on pain fMRI or on opioid receptor binding.
ISSN:2213-1582
2213-1582
DOI:10.1016/j.nicl.2017.11.011